Dallas, Texas (December 6, 2011) – StockGuru Shines its Spotlight on Biosign Technologies Inc. (TSX-V: BIO) and EasyMed Services, Inc. (CNSX: EZM) (OTCBB: EMYSF). The Companies announced Friday that they have executed a Letter of Intent to collaborate on a joint product offering and to enter into bilateral distribution of each other’s product offerings. EasyMed Services, Inc. closed on December 5, 2011, closed on December 5, 2011, at $0.82, trading in a fifty-two week range of $1.41 – 0.78.
Mobile Health (mHealth), an area of electronic health (eHealth), is the provisioning of health services and information via mobile technologies such as mobile phones, Personal Digital Assistants (PDAs) and smartphones. According to Research & Market 2009’s “U.S. Healthcare IT Market Analysis” study, the American mobile health market is estimated to be worth $2.1 billion at the end of 2011 and is expected to grow with a CAGR of nearly 22% from 2012 to 2014. Providing patient facing solutions for healthcare providers and payers is anticipated to open significant underserviced markets for both Biosign and EasyMed’s products.
Under the terms of the LOI:
- Biosign and EasyMed will enter into distribution and reseller agreements of each other’s product offerings;
- Biosign and EasyMed shall jointly develop new healthcare products and will share the revenue and intellectual property through a joint venture partnership;
- EasyMed shall become a mobile technology provider for Biosign’s future release of Healthanywhere™; and
- Biosign shall promote the “Powered by EasyMed” brand to be launched as part of these agreements.
Biosign intends to interface its UFIT® devices into Easy SmartCare from EasyMed and will make the offering available within North America. The platform provides benefits for payers, providers, and patients through improved patient preparation for medical visits, decreased absenteeism, better information for both the patient and the caregiver, improved communication of medical results to the patient, and enhanced outpatient management. As part of the platform, the easymedmobile app is available on the App Store from Apple; alternatively, users can sign up at www.easymedmobile.com.
EasyMed is a global medical information technology company delivering an end to end patient care solution through mobile phone/PDA and server technologies offering specialized services and applications for healthcare, insurance and pharmaceutical industries.
“As we move forward on focusing our business towards cardiovascular disease (CVD) management, it is imperative to address mobility in today’s age of anywhere, anytime customers.” stated Dr. Scott Jenkins, CEO of Biosign. “Our agreement with EasyMed enables us for mobility and marks a significant step towards our goal of becoming a leading technology provider for CVD management within the Healthcare IT ecosystem.”
Andy Ritchie, CEO of EasyMed commented, “Since 2005 EasyMed has worked diligently with major hospitals and healthcare providers to develop workflow driven solutions that reduce costs and provide better quality of care. The partnership between Biosign and EasyMed is very exciting because it brings together two great technologies which will allow us to deliver a leading edge new solution for patient care”.
The LOI is subject to the completion of definitive agreements, which are anticipated to be completed by December 31, 2011.
About EasyMed Services, Inc.
EasyMed Services, Inc. (CNSX: EZM) (OTCBB: EMYSF) provides technology solutions for healthcare organizations to enable the delivery of healthcare services on mobile devices while saving costs and improving operational efficiency. The technology platform implements the latest industry standards, is readily integrated into existing hospital environments, and complies with HIPAA and multi-national regulations.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, lifestyle, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign’s actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign’s filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031
e-mail: [email protected]